SecBot SecBot

KPTI drug pipeline

$0.0290
+16.0% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±34.7%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
1
1 bearish
Phase 3 trials
2
0 with results posted

Upcoming catalysts

2 dated
  1. Dec 2026
    Selinexor
    Phase 2 primary completion
  2. Dec 2026
    Selinexor (combination therapy)
    Phase 3 primary completion

Drugs

soonest catalyst first
▼ bearish
Impact
PhaseApproved
Time to marketAlready approved and commercialized (FDA approved April 2023 for hematologic malignancies; December 2025 for severe aplastic anemia).

Omisirge omidubicel-onlv Updated Nov 3

What to watch

Omisirge is already FDA-approved with no pending regulatory binary for this drug. The key event for KPTI holders is the Chapter 11 court-supervised sale process (confirmation hearing January 11, 2027) and the proposed merger with Ayrmid closing in Q1 2027, but existing KPTI equity is expected to receive zero recovery.

Bull case
  • Omisirge is the first FDA-approved allogeneic progenitor cell therapy for hematologic malignancies (April 2023) and the first cellular therapy for severe aplastic anemia (December 2025), addressing significant unmet needs.
  • The drug is a nicotinamide-modified cord blood therapy that reduces time to neutrophil recovery and infection incidence after transplant, with a differentiated mechanism.
  • Ayrmid (which owns Omisirge) has built a commercial platform with U.S. infrastructure and international distribution, and would bring Omisirge into the combined entity post-merger.
Bear case
  • KPTI filed for Chapter 11 bankruptcy on November 2, 2026; existing common stock will be canceled with zero recovery, per the 8-K filing.
  • Omisirge is not currently a Karyopharm asset; it is owned by Ayrmid Ltd./Gamida Cell, which is the merger partner, not the current KPTI entity.
  • KPTI stock closed at $0.088 on November 3, 2026, down ~21%, with a market cap around $20M, reflecting the expected equity wipeout.

Other drugs in filings and trials

no drug report yet
  • XPOVIO Last: Approval · Jul 3, 2019
  • Selinexor 3 trials

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
Jul 3, 2019XPOVIOApproval+34.7%+16.4%

Clinical trials

6 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
SelinexorSelinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Phase 2Active not recruiting244Dec 2026
Selinexor (combination therapy)A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaPhase 3Active not recruiting501Dec 2026
SelinexorA Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisPhase 2Active not recruiting112Sep 2026
Selinexor 100 mgRelative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination TreatmentPhase 2Completed · results80Jul 31, 2024
SelinexorSelinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 InhibitorsPhase 2Terminated · results17Aug 16, 2023
SelinexorMaintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]Phase 3Completed263Jan 22, 2022